Cited 10 times in
Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정희철 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 문용화 | - |
dc.contributor.author | 서창옥 | - |
dc.contributor.author | 양우익 | - |
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2015-08-26T16:41:04Z | - |
dc.date.available | 2015-08-26T16:41:04Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/114905 | - |
dc.description.abstract | BACKGROUND: The aim of this study was to evaluate the efficacy and safety of neoadjuvant chemotherapy with infusional 5-fluorouracil (5-FU), adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer (LABC). PATIENTS AND METHODS: Eighty-two LABC patients were treated with neoadjuvant iFAC chemotherapy including infusional 5-FU (1000 mg/m2, continuous intravenous infusion, days 1-3), adriamycin (40 mg/m2, intravenous bolus, day 1) and cyclophosphamide (600 mg/m2, intravenous bolus, day 1) every 3 weeks until maximum tumor response. Patients subsequently received surgery, adjuvant chemotherapy, radiotherapy and hormonal therapy as appropriate. RESULTS: Downstaging occurred in 71 of the 82 patients (86.6%). Seventy-two patients (67 patients with downstaging and five patients without downstaging) were resectable (resectability rate, 87.8%). The clinical response rate was 84.2%, with a complete response (CR) rate of 17.1% and a pathological CR rate of 7.8%. During 891 cycles of chemotherapy, the most common grade 3/4 hematological toxicity was leukopenia (36.0%). There were no treatment-related deaths. The median follow-up period was 51 months, with a median overall survival (OS) of 66 months, and a 5 year OS rate of 50.9% for all patients. The 5 year OS and disease-free survival (DFS) rates of the 64 patients who underwent surgery were 55.8% and 44.7%, respectively. CONCLUSIONS: Neoadjuvant chemotherapy with iFAC had a comparable response rate and DFS to the conventional bolus FAC regimen, with an acceptable toxicity in LABC using the AJCC 2002 staging system. An early response to neoadjuvant iFAC was a favorable prognostic factor. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1778~1785 | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Breast Neoplasms/drug therapy* | - |
dc.subject.MESH | Breast Neoplasms/pathology | - |
dc.subject.MESH | Breast Neoplasms/radiotherapy | - |
dc.subject.MESH | Breast Neoplasms/surgery | - |
dc.subject.MESH | Carcinoma, Ductal, Breast/drug therapy | - |
dc.subject.MESH | Carcinoma, Ductal, Breast/radiotherapy | - |
dc.subject.MESH | Carcinoma, Ductal, Breast/secondary | - |
dc.subject.MESH | Carcinoma, Ductal, Breast/surgery | - |
dc.subject.MESH | Carcinoma, Lobular/drug therapy | - |
dc.subject.MESH | Carcinoma, Lobular/radiotherapy | - |
dc.subject.MESH | Carcinoma, Lobular/secondary | - |
dc.subject.MESH | Carcinoma, Lobular/surgery | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Cyclophosphamide/administration & dosage | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Doxorubicin/administration & dosage | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intravenous | - |
dc.subject.MESH | Maximum Tolerated Dose | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoadjuvant Therapy* | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Radiotherapy Dosage | - |
dc.subject.MESH | Survival Rate | - |
dc.title | Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Y. W. Moon | - |
dc.contributor.googleauthor | S. Y. Rha | - |
dc.contributor.googleauthor | H. C. Chung | - |
dc.contributor.googleauthor | C. O. Suh | - |
dc.contributor.googleauthor | W. I. Yang | - |
dc.contributor.googleauthor | H. C. Jeung | - |
dc.identifier.doi | 10.1093/annonc/mdi360 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01370 | - |
dc.contributor.localId | A01919 | - |
dc.contributor.localId | A02300 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A03794 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.pmid | 16091429 | - |
dc.subject.keyword | adriamycin | - |
dc.subject.keyword | cyclophosphamide | - |
dc.subject.keyword | infusional 5-fluorouracil | - |
dc.subject.keyword | locally advanced breast cancer | - |
dc.subject.keyword | neoadjuvant chemotherapy | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Moon, Yong Wha | - |
dc.contributor.alternativeName | Suh, Chang Ok | - |
dc.contributor.alternativeName | Yang, Woo Ick | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Moon, Yong Wha | - |
dc.contributor.affiliatedAuthor | Suh, Chang Ok | - |
dc.contributor.affiliatedAuthor | Yang, Woo Ick | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 16 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1778 | - |
dc.citation.endPage | 1785 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.16(11) : 1778-1785, 2005 | - |
dc.identifier.rimsid | 39301 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.